Company News: Page (1) of 1 - 02/26/14

Free VIDEO B-ROLL AVAILABLE VIA CNW - Bexsero®: First Vaccine to Prevent Meningococcal Serogroup B (MenB) Now Available in Canada


February 26, 2014 --

TORONTO, Feb. 26, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download:

STORY SUMMARY:  Novartis announced today that Bexsero® (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) is now available to doctors and pharmacists across Canada. The vaccine is approved for use in individuals from two months through 17 years of age in Canada. Infants, toddlers and adolescents are at the greatest risk of meningococcal serogroup B (MenB) infection. Bexsero® is the first broad-coverage vaccine to help protect against MenB disease. Prior to Bexsero®, vaccines were only available to help protect against meningococcal strains A, C, W and Y.

Full Press Release:

WEB Video Preview and Download link:

TIME OF POSTING:   Available Now
DATE OF POSTING:   02/26/2014

All video can be viewed by clicking on the link. Broadcast quality video is available for download by accredited journalists. Please contact [email protected] for access.


Abigail Bueno
Weber Shandwick
416 642 7893
[email protected]

For assistance with Video On-Demand, please contact CNW at [email protected] or (416) 863-5612.

CNW Video On-Demand provides free, secure and easy-to-use broadcast quality material direct from our website to accredited journalists worldwide.

This material is offered for free and unrestricted news use.


SOURCE Novartis Pharmaceuticals Canada Inc.

Video with caption: "Video: Bexsero®: First Vaccine to Prevent Meningococcal Serogroup B (MenB) Now Available in Canada". Video available at:

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1
Related Keywords:Canada, Disease, Surgery, Science, Internet Technology, Medical,

Source:PR Newswire. All Rights Reserved

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved

Digital Media Online, Inc.